Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Leukemias

A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia

Leukemia volume 29, pages 1069–1075 (2015)Cite this article

Subjects

Abstract

The use of unmanipulated graft is increasingly adopted in the setting of allogeneic hematopoietic stem cell transplantation from haploidentical family donors (haplo-SCT) in acute leukemia (AL). We analyzed the outcome of 229 adult patients with de novo AL, who received an unmanipulated haploidentical transplant as their first allo-SCT between 2007 and 2011. Median follow-up was 30 months. Disease status at transplant was: first complete remission (CR1) for 77, second CR (CR2) for 56, and advanced for 96 patients. One hundred and seventy-one patients received in vivo T-cell depletion by monoclonal antibodies (75%). The 60-day cumulative incidence (CI) of engraftment was 93±2%. The 100-day CI of acute graft-versus-host disease (GvHD) was 32±3% for grade II–IV, 12±3% for grade III–IV. The 3-year CI of chronic GvHD was 34±3%. The 3-year CI of non-relapse mortality was 31±4% with in vivo T-cell depletion and 17±5% without. At 3 years, for patients transplanted in CR1, CR2 or advanced disease leukemia-free survival was 44±6, 42±7 and 12±3%, overall survival was 55±6, 51±7 and 14±4% and CI of relapse was 32±6, 24±6 and 61±5%, respectively. These data suggest that unmanipulated haplo-SCT is a valid treatment option for adult AL patients in complete remission lacking a matched donor.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Mrozek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 2012; 30: 4515–4523.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ballen KK, Spitzer TR . The great debate: haploidentical or cord blood transplant. Bone Marrow Transplant 2011; 46: 323–329.

    Article  CAS  PubMed  Google Scholar 

  3. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765–771.

    Article  CAS  PubMed  Google Scholar 

  4. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197–204.

    Article  CAS  PubMed  Google Scholar 

  5. O’Reilly RJ, Kernan NA, Cunningham I . Allogeneic transplants depleted of T cells by soybean lectin agglutination and E-rosette depletion. Bone Marrow Transplant 1988; 3: 3–6.

    Google Scholar 

  6. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C et al. Successful engraftment of T-cell depleted haploidentical three loci incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony stimulating factor mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948–3955.

    CAS  PubMed  Google Scholar 

  7. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186–1193.

    Article  CAS  PubMed  Google Scholar 

  8. Aversa F, Terenzi A, Carotti A, Felicini R, Jacucci R, Zei T et al. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. J Clin Oncol 1999; 17: 1545–1550.

    Article  CAS  PubMed  Google Scholar 

  9. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112: 3574–3581.

    Article  CAS  PubMed  Google Scholar 

  10. Champlin R, Hesdorffer C, Lowenberg B, Martelli MF, Mertelsmann RH, Reisner Y et al. Haploidentical 'megadose' stem cell transplantation in acute leukaemia: recommendations for a protocol agreed upon at the Perugia and Chicago meetings. Leukemia 2002; 16: 427–428.

    Article  CAS  PubMed  Google Scholar 

  11. Waller EK, Giver CR, Rosenthal H, Somani J, Langston AA, Lonial S et al. Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. Blood Cells Mol Dis 2004; 33: 233–237.

    Article  CAS  PubMed  Google Scholar 

  12. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukaemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–3454.

    Article  PubMed  Google Scholar 

  13. Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical stem-cell transplantation for leukemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489–500.

    Article  PubMed  Google Scholar 

  14. Ji SQ, Chen HR, Wang HX, Yan HM, Zhu L, Liu J et al. G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia. Bone Marrow Transplant 2002; 30: 861–866.

    Article  PubMed  Google Scholar 

  15. Lee KH, Lee JH, Kim DY, Kim SH, Shin HJ, Lee YS et al. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex-vivo T-cell depletion after reduced-intensity conditioning with busulfan, fludarabine and antithymocyte globulin. Biol Blood Marrow Transplant 2009; 15: 61–72.

    Article  CAS  PubMed  Google Scholar 

  16. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065–3073.

    Article  CAS  PubMed  Google Scholar 

  17. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood and Marrow Transplant 2013; 19: 117–122.

    Article  CAS  Google Scholar 

  19. Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013; 121: 849–857.

    Article  CAS  PubMed  Google Scholar 

  20. Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MTL et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 2014; e-pub ahead of print 4 June 2014; doi:10.1038/leu.2014.180.

    Article  PubMed  Google Scholar 

  21. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on AGvHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  22. Lee SJ, Vogelsang G, Flowers ME . Chronic graft versus host disease. Biol Blood Marrow Transplant 2003; 9: 215–233.

    Article  CAS  PubMed  Google Scholar 

  23. Kaplan EL, Meier P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  24. Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706.

    Article  CAS  PubMed  Google Scholar 

  25. Mantel N . Evaluation of survival data and two new rank order statitics arising in its consideration. Cancer Chemother Rep 1996; 503: 163–170.

    Google Scholar 

  26. Fine JP, Gray RJ . A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.

    Article  Google Scholar 

  27. Cox DR . Regression models and life tables. J R Stat Soc 1972; 34: 187–202.

    Google Scholar 

  28. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.

    Article  PubMed  Google Scholar 

  29. Rowe JM . Prognostic factors in adult acute lymphoblastic leukemia. Br J Haematol 2010; 150: 389–405.

    PubMed  Google Scholar 

  30. Ringdén O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 4570–4577.

    Article  PubMed  Google Scholar 

  31. Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J . Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 2012; 119: 3908–3916.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical sibling. J Clin Oncol 1997; 15: 1767–1777.

    Article  CAS  PubMed  Google Scholar 

  33. Gorin NC, Labopin M, Rocha V, Arcese W, Beksac M, Gluckman E et al. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocitic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood 2003; 102: 3043–3051.

    Article  CAS  PubMed  Google Scholar 

  34. Flower ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW et al. Comparative analysis of risk factors for acute graft-versus-host disease Institutes of Health consensus criteria and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117: 3214–3219.

    Article  Google Scholar 

  35. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012; 119: 296–307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Luznik L, O’Donnel PV, Fuchs JE . Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical BMT. Semin Oncol 2012; 39: 1–16.

    Article  Google Scholar 

  37. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25: 690–697.

    Article  CAS  PubMed  Google Scholar 

  38. van Rood JJ, Loberiza FR Jr, Zhang MJ, Oudshoorn M, Claas F, Cairo MS et al. Effect of tolerance to non-inherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood 2002; 99: 1572–1577.

    Article  PubMed  Google Scholar 

  39. Wang Y, Chang Y-J, Xu L-P, Liu K-Y, Liu D-H, Zhang X-H et al. Who is the best donor for a related HLA- haplotype-mismatched transplant? Blood 2014; 124: 843–850.

    Article  CAS  PubMed  Google Scholar 

  40. Wang Y, Liu D-H, Liu K-Y, Xu L-P, Zhang X-H, Han W et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia. Cancer 2013; 119: 978–985.

    Article  PubMed  Google Scholar 

  41. Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolaños-Meade J et al. Nonmyeloablative HLA-haploidentical BMT with high-dose postransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010; 16: 482–489.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Brunstein CG, Fuchs EJ, Carter SJ, Karanes C, Costa LJ, Wu J et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011; 118: 282–288.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank all the allogeneic transplantation centers of the EBMT group for reporting the data included in this analysis to this registry. A list of the participating EBMT centers appears in the Appendix.

Author Contributions

SP designed research, collected and checked the data, contacted transplantation centers, analyzed data and wrote the paper; ML designed research, analyzed data and wrote the paper; FC designed research and wrote the paper; AB and JT provided data and wrote the paper; N-CG wrote the paper; HH SS, YK, WD, BD, EG and WA provided data; AN and MM wrote the paper.

Author information

Authors and Affiliations

  1. Hematology and Bone Marrow Transplant Unit, San Raffaele Scientific Institute, Milan, Italy

    S Piemontese & F Ciceri

  2. EBMT Paris Office, Hosital Saint Antoine, Paris, France

    S Piemontese, F Ciceri, M Labopin, N-C Gorin, A Nagler & M Mohty

  3. AP-HP, Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France

    M Labopin, N-C Gorin & M Mohty

  4. Sorbonne Niversité, UPMC Univ Paris 06, UMR_S 938, CDR Saint-Antoine, Paris, France

    M Labopin, N-C Gorin & M Mohty

  5. INSERM, MR_S 938, CDR Saint-Antoine, Paris, France

    M Labopin, N-C Gorin & M Mohty

  6. Division of Hematology II, IRCCS, San Martino University Hospital—IST, Genoa, Italy

    A Bacigalupo

  7. Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    H Huang

  8. Department of Hematology, Ospedale Civile, Pescara, Italy

    S Santarone

  9. Hematopoietic Stem Cell Transplantation Unit, Medical Park Hospital, Antalya, Turkey

    Y Koc

  10. The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, Suzhou, China

    D Wu

  11. Department of Bone Marrow Transplantation, University Hospital, Essen, Germany

    D Beelen

  12. Department of Internal Medicine III, University Hospital of Munich-Klinikum Grosshadern (LMU), Hematopoietic Cell Transplantation, Munich, Germany

    J Tischer

  13. Medizinische Klinik und Poliklinik I, Universitaetsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany

    G Ehninger

  14. Stem Cell Transplant Unit, Fondazione Policlinico Tor Vergata, Tor Vergata University, Rome, Italy

    W Arcese

  15. Chaim Sheba Medical Center, Tel-Hashomer, Israel

    A Nagler

Authors
  1. S Piemontese
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Ciceri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Labopin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Bacigalupo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Santarone
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N-C Gorin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y Koc
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Beelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Tischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. G Ehninger
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. W Arcese
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT)

Corresponding author

Correspondence to S Piemontese.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Appendix

Appendix

EBMT participating centers: Hematology and Bone Marrow Transplant Unit, San Raffaele Hospital, Milan (61 patients); Stem Cell Transplant Unit, Fondazione Policlinico Tor Vergata, Tor Vergata University, Rome, Italy (30 patients); Division of Hematology II, IRCCS, San Martino University Hospital—IST, Genoa, Italy (21 patients); The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China (17 patients); Department of Hematology, Ospedale Civile, Pescara, Italy (16 patients); Hematopoietic Stem Cell Transplantation Unit, MedicalPark Hospital, Antalya, Turkey (13 patients); First Affiliated Hospital of Soochow University, Suzhou, China (13 patients); Department of Bone Marrow Transplantation, University Hospital, Essen, Germany (8 patients); University Hospital of Munich-Klinikum Grosshadern (LMU), Department of Internal Medicine III, Hematopoietic Cell Transplantation, Munich, Germany (6 patients); Medizinische Klinik und Poliklinik I, Universitaetsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany (6 patients); Azienda Ospedaliera, Reggio Calabria, Italy (5 patients); University Hospital Gasthuisberg, Leuven, Belgium (4 patients); Azienda Ospedali Riuniti di Ancona, Ancona-Torrete, Italy (4 patients); University Hospital, Basel, Switzerland (3 patients); University Hospital, Udine, Italy (3 patients); Gazi Universitesi Tip Fakültesi, Ankara, Turkey (2 patients); University Med. Center, Ljubljana, Slovenia (2 patients); Heilig Hartziekenhuis, Roeselare, Belgium (2 patients); Tel-Aviv University, Tel-Hashomer, Israel (2 patients); Hospital Guglielmo da Saliceto, Piacenza, Italy (1 patient); Universität Tübingen, Tübingen, Germany (1 patient); Unité de transplantation et de thérapie cellulaire, Marseille, France (1 patient); Ospedale S. Camillo-Forlanini, Rome, Italy (1 patient); Centre For Clinical Haematology, Birmingham, United Kingdom (1 patient); King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia (1 patient); Helsinki University Central Hospital, Helsinki, Finland (1 patient); University Hospital Eppendorf, Hamburg, Germany (1 patient); Shariati Hospital,Teheran, Iran (1 patient); Umea University Hospital, Umeå, Sweden (1 patient); and University of Freiburg, Freiburg, Germany (1 patient).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Piemontese, S., Ciceri, F., Labopin, M. et al. A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. Leukemia 29, 1069–1075 (2015). https://doi.org/10.1038/leu.2014.336

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.336

This article is cited by

Search

Advanced search

Quick links